[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Berzofsky, 2014 - Google Patents

116 Strategies and mechanisms for vaccine induction of mucosal T cell immunity

Berzofsky, 2014

View PDF
Document ID
5275913335192331100
Author
Berzofsky J
Publication year
Publication venue
JAIDS Journal of Acquired Immune Deficiency Syndromes

External Links

Snippet

Most HIV transmission is through mucosal surfaces. We previously found in mice that CD8 T cells must be in the local mucosa to prevent mucosal viral transmission. Intrarectal delivery was most effective, but not so practical. We devised a strategy to mimic intrarectal delivery …
Continue reading at pmc.ncbi.nlm.nih.gov (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse Transcribing RNA Viruses
    • C12N2740/00011—Reverse Transcribing RNA Viruses
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16023—Virus like particles [VLP]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus

Similar Documents

Publication Publication Date Title
Tkachuk et al. 109 Problems and prospects of development of the subunit TB vaccine
Gudima et al. 102 HIV/AIDS vaccines in Russia: clinical trials and estimation of acceptance in population
Zhang 121 Progress, achievements and challenges: a review of China’s free antiretroviral therapy program
Kofiadi et al. 103 Genetic factors defining resistance and susceptibility to HIV/AIDS
Kochetkov 120 Development of New HIV Inhibitors
Chaplinskas 147 Globalization and New Challenges Caused of Communicable Diseases
Vahlne 122 Peptide Inhibitors of HIV
Karamov et al. 101 Biomedical Prevention of HIV/AIDS in Russia
Lanzavecchia 110 Broadly neutralizing antibodies for serotherapy and vaccine design
Xiuling et al. 112 The Development of Enterovirus 71 Vaccine
Bichko 127 Safety, pharmokinetics and efficacy of VM-1500, a novel reverse transcriptase inhibitor, In healthy volunteers and HIV-infected patients
Lafeuillade 125 Progress Toward A Cure for HIV
Margolis 124 Male-to-Female HIV-1 Transmission: Lessons from Ex Vivo
Bogorodskaya 161 Anti-tuberculosis Treatment for HIV-positive Patients in Moscow
Korobova et al. 107 The modern methods for HIV/AIDS vaccine evaluation
Berzofsky 116 Strategies and mechanisms for vaccine induction of mucosal T cell immunity
Mazurov et al. 104 Cell-to-cell transmission of HIV: role of virological synapse
Matsuoka 153 Molecular pathogenesis by HTLV-1 bZIP factor
Balzarini 118 The dense glycan shield on the HIV envelope: the Achilles heel of the virus?
Rooney et al. 123 New HIV Therapies
Schmidt 111 Update on dengue vaccines
Peters 156 HIV and metabolic disease: Clues to control of HIV infection from the immune and virological response to high dose Vitamin D challenge
Beaty 139 Dengue vector control: critical needs and opportunities for helping to control the dengue pandemic
Gilliam 160 Treatment Strategies to Minimize the Impact of Antiretroviral Drug Toxicities
Lin et al. 138 Understanding protective immunity: Lessons from measles